Papillomavirus-like particle vaccines.
Papillomavirus-like particle (VLP)-based subunit vaccines have undergone rapid development over the past 8 years. Three types are being investigated. The most basic type is composed of only the L1 major capsid protein and is designed to prevent genital human papillomavirus (HPV) infection by inducing virus-neutralizing antibodies. On the basis of positive results in animal models, clinical trials of this type of vaccine for HPV16, and other types, are currently under way. Preliminary results have been encouraging in that systemic immunization with the L1 VLPs induced high serum titers of neutralizing antibodies without substantial adverse effects. The second type of vaccine incorporates other papillomavirus polypeptides into the VLPs as L1 or L2 fusion proteins. These chimeric VLPs are designed to increase the therapeutic potential of an HPV vaccine by inducing cell-mediated responses to nonstructural viral proteins, such as E7. Studies in mice indicate that these vaccines generate potent antitumor cytotoxic lymphocyte (CTL) responses while retaining the ability to induce high-titer neutralizing antibodies. It is likely that prophylactic and therapeutic clinical trials of chimeric VLPs will be initiated in the near future. The third type of VLP-based vaccine is designed to induce autoantibodies against central self-antigens by incorporating self-peptides into the outer surface of VLPs, a process that could have therapeutic potential in various disease settings unrelated to HPV infection. In a recent proof of concept study, a peptide from an external loop of mouse CCR5 protein was inserted into a neutralizing epitope of L1. In mice, the particles generated by this chimeric L1 were able to induce high titers of CCR5 antibodies that specifically recognized the surface of CCR5-transfected cells and blocked in vitro infection of an M-tropic human immunodeficiency virus strain.
Schiller
J T
JT
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892, USA. schillej@dc37a.nci.nih.gov
Lowy
D R
DR
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D001323:Autoantibodies / Q000096:biosynthesis; D036022:Capsid Proteins; D002986:Clinical Trials as Topic; D003602:Cytotoxicity, Immunologic; D005260:Female; D015658:HIV Infections / Q000517:prevention & control; D006801:Humans; D007114:Immunization; D008297:Male; D051379:Mice; D009856:Oncogene Proteins, Viral / Q000276:immunology; D027383:Papillomaviridae / Q000276:immunology* / Q000648:ultrastructure; D030361:Papillomavirus Infections / Q000517:prevention & control; D053918:Papillomavirus Vaccines; D011817:Rabbits; D019713:Receptors, CCR5 / Q000276:immunology; D015728:Receptors, HIV / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000276:immunology; D015229:Sexually Transmitted Diseases, Viral / Q000517:prevention & control; D014162:Transfection; D014412:Tumor Virus Infections / Q000517:prevention & control; D022223:Vaccines, Subunit / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology; D014771:Virion / Q000648:ultrastructure
D000914:Antibodies, Viral; D001323:Autoantibodies; D036022:Capsid Proteins; D009856:Oncogene Proteins, Viral; D053918:Papillomavirus Vaccines; D019713:Receptors, CCR5; D015728:Receptors, HIV; D011993:Recombinant Fusion Proteins; D022223:Vaccines, Subunit; D014765:Viral Vaccines; C063317:L1 protein, Human papillomavirus type 16